COMMUNIQUÉS West-GlobeNewswire

BioVie Inc. (OTCQB:BIVI) Attains Milestone
09/04/2018
Company Reaches 50% Patient Enrollment in Phase 2a Clinical Trial of BIV201 for Refractory Ascites BEVERLY, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the [...]
Auris Medical Announces Early Repayment of Part of its Loan Facility
09/04/2018
Zug, Switzerland, April 9, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced the [...]
PotNetwork Holding, Inc.'s Diamond CBD, Inc. to be featured at 2018 Telecom Review Summit held in Beirut, Lebanon.
09/04/2018
Exponential, Inc. founder and CEO Dom Einhorn to present keynote panel, “The New Start-Up Ecosystem”. FT LAUDERDALE, Fla., April 09, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--PotNetwork Holding, Inc. (OTC Pink:POTN) On [...]
ContraVir Pharmaceuticals Appoints Two New Hepatitis B Experts to Scientific Advisory Board
09/04/2018
EDISON, N.J., April 09, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced [...]
RavenQuest Common Shares Listed on OTC now DTC Eligible
09/04/2018
VANCOUVER, British Columbia, April 09, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) (OTCQB:RVVQF) (Frankfurt: 1IT ) today announced that it has secured DTC Eligibility for [...]
Enzymatica AB: New ColdZyme study in elite athletes confirms preventive effect and reduced duration of illness
09/04/2018
News Lund April 9, 2018 New ColdZyme study in elite athletes confirms preventive effect and reduced duration of illness Enzymatica is now publishing the results of a second study 1 in which elite athletes used ColdZyme [...]
Transactions under Novozymes’ stock buyback program
09/04/2018
Please read the full announcement in the attached PDF Attachment 2018_12_Stock_Buybackprogram_EN
MPI - Oncology Venture exercises option to inlicense Dovitinib a Phase 3 Multi Tyrosine Kinase Inhibitor
09/04/2018
Hoersholm, Denmark, April 9, 2018 - Medical Prognosis Institute A/S (MPI:ST) ("MPI" or the "Company") today announced that Oncology Venture has entered into an agreement with Novartis Pharma AG (Basel, Switzerland) for [...]
Solon Eiendom ASA : Strategic equity investment by Union - and subsequent offering
09/04/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR [...]
Solon Eiendom ASA : KEY INFORMATION RELATING TO THE SUBSEQUENT OFFERING
09/04/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR [...]
RECORDATI ACQUIRES INTERNATIONAL RIGHTS TO CYSTAGON® FROM MYLAN
09/04/2018
Milan, 9 April 2018 - Recordati announces the completion of an agreement with Mylan for the acquisition of the rights to Cystagon® (cysteamine bitartrate), indicated for the treatment of proven nephropathic cystinosis [...]
Shire plc : Rule 2.9 Announcement
09/04/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 9 April 2018 Shire [...]
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma
09/04/2018
Basel, Switzerland, April 09, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its partner Avir Pharma Inc. ("Avir Pharma") has launched Basilea's hospital antibiotic Zevtera ® (ceftobiprole) in Canada [...]
INNATE PHARMA : Upcoming investor conferences
09/04/2018
upcoming investor conferences Marseille, France, April 9, 2018, 7:00 AM CEST Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that it will be present at the following investor events [...]
INNATE PHARMA : Prochains rendez-vous investisseurs
09/04/2018
PROCHAINS RENDEZ-VOUS INVESTISSEURS Marseille, le 9 avril 2018, 7h00 CEST Innate Pharma SA (Euronext Paris : FR0010331421 - IPH) annonce aujourd'hui qu'elle sera présente aux événements investisseurs suivants : H.C. [...]
argenx appoints Keith Woods as Chief Operating Officer
09/04/2018
April 9, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
09/04/2018
AveXis lead product candidate, AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong disability with [...]
AveXis Enters Agreement to be Acquired by Novartis AG for $8.7 billion
09/04/2018
Novartis to acquire AveXis for $218 per share in cash AveXis’ lead product candidate, AVXS-101, expected to enhance Novartis’s position as a gene therapy and neuroscience leader Transaction expected to be completed in [...]
Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis
09/04/2018
Company to Host Conference Call Monday, April 9 at 4:00am PT / 7:00am ET REDWOOD CITY, Calif., April 08, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO ), a late-stage biopharmaceutical company focused [...]

Pages